Background: Randomized clinical trials have demonstrated the benefits of\nchemotherapy in carefully selected non-small cell lung cancer (NSCLC) patients.\nHow generalizable these results are to other NSCLC patients is unresolved.\nMethods: The outcomes of patients treated with standard chemotherapy regimens\n(paclitaxel/carboplatin; gemcitabine/carboplatin; pemetrexed/carboplatin;\npaclitaxel/carboplatin/bevacizumab) off study as first line therapy between\n2002 and 2012 at our institution were compared to the reported results of trials\nsupporting the FDA approval of these drugs and/or regimens. Results: In\nour population, 38.1% of the patients had hypertension, 11.9% of the patients\nwere diabetic, 23.7% had chronic obstructive pulmonary disease (COPD),\n11.9% had coronary artery disease (CAD) and 2.1% had renal or liver disease.\nNotably, the presence of a single or multiple comorbidities was associated\nwith low overall survival compared to matched patients with no comorbidities\n(p = 0.007). Conclusion: The presence of single or multiple comorbidities is\nassociated with inferior overall survival compared to matched groups without\nsuch pre-existing conditions.
Loading....